Reshaping the HIV treatment and prevention landscape

From historical underperformance to ambitious top quartile growth Revenues Adj OP R&D spend gsk Company sales CAGR to 2026* 2010 - 2015 2016 - 2020 2021 - 2026 Company 1 Company 2 New GSK Company 4 Company 5 Company 6 Company 7 Company 8 Company 9 Company 10 Company 11 Company 12 Company 13 Company 14 Company 15 -4.0% -2.0% 0.0% 2.0% 4.0% 6.0% 8.0% 10.0% More than 5% sales and 10% adjusted operating profit CAGR expected in next 5 years * Visible Alpha company consensus to 2026 All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. See basis of preparation and assumptions in Appendix. 2021-26 CAGR is for the 5 years to 2026, using 2021 as the base year. Pipeline sales are risk-adjusted and include anticipated sales of new products and Life Cycle Innovation (LCI) launched from 2021 onwards. Note: COVID therapeutic and vaccine solutions are excluded from the above. 14

View entire presentation